Characterization of opioid overdose and response in a high-risk community corrections sample: A preliminary study

Journal of Opioid Management

Volumn 9, Issue 6, 2013, Pages 393-400

  Cropsey, Karen L ^a   Martin, Stephen ^b   Clark, C Brendan ^a   McCullumsmith, Cheryl B ^a   Lane, Peter S ^a   Hardy, Sonya ^a   Hendricks, Peter S ^c   Redmond, Nicole ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Community corrections; Criminal justice; Opiates; Overdose

Indexed keywords

ADULT; ALABAMA; ANALGESICS, OPIOID; CHI-SQUARE DISTRIBUTION; DRUG OVERDOSE; DRUG USERS; FEMALE; HEALTH BEHAVIOR; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PATIENT EDUCATION AS TOPIC; PRISONERS; RISK FACTORS; TIME FACTORS; VULNERABLE POPULATIONS; YOUNG ADULT;

EID: 84893952545     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2013.0181     Document Type: Article

References (35)

1. Anon.: Community-based opioid overdose prevention programs providing naloxone - United States, 2010. Morb Mortal Wkly Rep. 2012; 61(6): 101-105.
2. Anon.: Vital signs: Overdoses of prescription opioid pain relievers - United States, 1999-2008. Morb Mortal Wkly Rep. 2011; 60(43): 1487-1492.
3. Seaman SR, Brettle RP, Gore SM: Mortality from overdose among injecting drug users recently released from prison: Database linkage study. BMJ. 1998; 316(7129): 426-428. (Pubitemid 28121295)
4. Binswanger IA, Blatchford PJ, Lindsay RG, et al.: Risk factors for all-cause, overdose and early deaths after release from prison in Washington state. Drug Alcohol Depend. 2011; 117(1): 1-6.
5. Binswanger IA, Stern MF, Deyo RA, et al.: Release from prison - A high risk of death for former inmates. N Engl J Med. 2007; 356(2): 157-165. (Pubitemid 46089676)
6. Spaulding AC, Seals RM, McCallum VA, et al.: Prisoner survival inside and outside of the institution: Implications for health-care planning. Am J Epidemiol. 2011; 173(5): 479-487.
7. Merrall ELC, Kariminia A, Binswanger IA, et al.: Meta-analysis of drug-related deaths soon after release from prison. Addiction. 2010; 105(9): 1545-1554.
8. Kim D, Irwin KS, Khoshnood K: Expanded access to naloxone: Options for critical response to the epidemic of opioid overdose mortality. Am J Public Health. 2009; 99(3): 402-407.
9. Enteen L, Bauer J, McLean R, et al.: Overdose prevention and naloxone prescription for opioid users in San Francisco. J Urban Health. 2010; 87(6): 931-941.
10. Wermeling DP: Opioid harm reduction strategies: Focus on expanded access to intranasal naloxone. Pharmacotherapy. 2010; 30(7): 627-631.
11. Ahalt C, Binswanger IA, Steinman M, et al.: Confined to ignorance: The absence of prisoner information from nationally representative health data sets. J Gen Intern Med. 2012; 27(2): 160-166.
12. Cropsey KL, Jones-Whaley S, Jackson DO, et al.: Smoking characteristics of community corrections clients. Nicotine Tob Res. 2010; 12(1): 53-58.
13. Clark BC, Perkins A, McCullumsmith CB, et al.: What does self-identified drug of choice tell us about individuals under community corrections supervision? J Addict Med. 2012; 6(1): 57-67.
14. Green TC, Heimer R, Grau LE: Distinguishing signs of opioid overdose and indication for naloxone: An evaluation of six overdose training and naloxone distribution programs in the United States. Addiction. 2008; 103(6): 979-989. (Pubitemid 351703471)
15. Baca CT, Grant KJ: Take-home naloxone to reduce heroin death. Addiction. 2005; 100(12): 1823-1831. (Pubitemid 41775207)
16. Hakansson A, Schlyter F, Berglund M: Factors associated with history of non-fatal overdose among opioid users in the Swedish criminal justice system. Drug Alcohol Depend. 2008; 94: 48-55.
17. Goldstein A, Herrera J: Heroin addicts and methadone treatment in Albuquerque: A 22-year follow-up. Drug Alcohol Depend. 1995; 40(2): 139-150. (Pubitemid 26011977)
18. Smyth B, Hoffman V, Fan J, et al.: Years of potential life lost among heroin addicts 33 years after treatment. Prev Med. 2007; 44(4): 369-374. (Pubitemid 46550676)
19. Grella CE, Lovinger K: 30-Year trajectories of heroin and other drug use among men and women sampled from methadone treatment in California. Drug Alcohol Depend. 2011; 118(2-3): 251-258.
20. Jimenez-Treviño L, Saiz PA, García-Portilla MP, et al.: A 25-year follow-up of patients admitted to methadone treatment for the first time: Mortality and gender differences. Addict Behav. 2011; 36(12): 1184-1190.
21. Dhalla I a, Mamdani MM, Sivilotti ML a, et al.: Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ. 2009; 181(12): 891-896.
22. Warner M, Chen LH, Makuc DM: Increase in Fatal Poisonings Involving Opioid Analgesics in the United States, 1999-2006. NCHS Data Brief, September 2009. Available at http://www.cdc.gov/nchs/data/databriefs/db22.pdf. Accessed September 19, 2013.
23. Center for Disease Control and Prevention: Prescription Painkiller Overdoses: Use and Abuse of Methadone as a Painkiller. July 2012. Available at http://www.cdc.gov/vitalsigns/MethadoneOverdoses/. Accessed September 19, 2013.
24. McIntosh C, Ritson B: Treating depression complicated by substance misuse. Adv Psychiatr Treat. 2001; 7: 357-364. (Pubitemid 32927163)
25. Cropsey KL, Lane PS, Hale GJ, et al.: Results of a randomized controlled trial of buprenorphine for opioid dependent women in the criminal justice system. Drag Alcohol Depend. 2011; 119: 172-178.
26. Wright NM, Shead L, Adams CE, et al.: Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): A randomized controlled trial. Br J Gen Pract. 2011; 61(593): e772-e780.
27. Magura S, Lee JD, Hershberger J, et al.: Buprenorphine and methadone maintenance in jail and post-release: A randomized clinical trial. Drug Alcohol Depend. 2009; 99: 222-230.
28. Garcia CA, Correa GC, Viver AD, et al.: Buprenorphine-naloxone treatment for pre-release opioid-dependent inmates Puerto Rico. J Addict Med. 2007; 1(3): 126-132.
29. Darke S, Ross J, Hall W: Overdose among heroin users in Sydney, Australia: II. Responses to overdose. Addiction. 1996; 91(3): 413-417. (Pubitemid 26082858)
30. Hoffman RS: Toxicology from across the pond. J R Coll Physicians Edinb. 2010; 40(2): 152-158.
31. Inciardi JA: The War on Drugs IV. Boston: Pearson, Allyn & Bacon, 2007.
32. Bjornaas MA, Teige B, Hovda KE, et al.: Fatal poisonings in Oslo: A one-year observational study. BMC Emerg Med. 2010; 10: 13.
33. Spertus JA, Ross JS, Curtis JP, et al.: Reduction in acute myocardial infarction mortality in the United States. JAMA. 2009; 302(7): 767-773.
34. Choudhry NK, Avorn J, Glynn RJ, et al.: Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011; 365(22): 2088-2097.
35. Weisfeldt ML, Sitlani CM, Ornato JP, et al.: Survival after application of automatic external defibrillators before arrival of the emergency medical system: Evaluation in the resuscitation outcomes consortium population of 21 million. J Am Coll Cardiol. 2010; 55(16): 1713-1720.